{"id":"W2129931005","doi":"10.1200/jco.2007.13.4452","title":"Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033","year":2008,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Gastrointestinal Tumor Research and Treatment","field":"Medicine","cited_by":1077,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"National Cancer Institute; U.S. Public Health Service","keywords":"Medicine; Imatinib mesylate; Imatinib; GiST; Regimen; Internal medicine; Surgery; Oncology; Phases of clinical research; Clinical trial; Gastroenterology; Tyrosine-kinase inhibitor; Progression-free survival; Chemotherapy; Stromal cell; Cancer","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null}